RARE

#1581
Ultragenyx Pharmaceutical Inc. - Common Stock
23.9 4 USD
+2.92%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
23.94
23.94
Rango anual
18.29
42.37
Cambio diario
+2.92%
Variación mensual
-2.17%
Variación en los últimos 6 meses
-29.98%
Cambio anual
-31.34%
Cierres anteriores
23.2 6
Open
23.9 4
Mínimo
23.9 4
High
23.9 4
Volumen
142
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA.

Noticias